GlassScriptPhysician profile
Mariana Danet
NPI 1649336660
$8,691.47
in general payments reported to CMS, 2019-2025
32 companies · $1,279 in 2025
The $1,279 reported for 2025 was more than what 84% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $932 · 2020: $996 · 2021: $1,485 · 2022: $897 · 2023: $1,809 · 2024: $1,293 · 2025: $1,279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,370 · Education: $11.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,369.74 |
| Education | $11.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,399.49 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Mycite |
| Abbvie INC. | $1,121.19 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,010.76 | 2020-2025 | Caplyta |
| Lundbeck LLC | $677.09 | 2019-2025 | Rexulti |
| Alkermes, INC. | $664.71 | 2019-2025 | Lybalvi, Aristada |
| Allergan, INC. | $598.16 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $520.28 | 2019-2025 | Spravato, Invega Trinza, Invega |
| Sunovion Pharmaceuticals INC. | $421.13 | 2019-2022 | |
| Almatica Pharma LLC | $321.16 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Takeda Pharmaceuticals U.S.A., INC. | $309.41 | 2019-2021 | |
| Axsome Therapeutics, INC. | $234.43 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $161.64 | 2024 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $156.98 | 2019-2023 | Uzedy, Austedo Xr |
| Tris Pharma INC | $137.20 | 2023-2025 | Dyanavel Xr |
| Bausch Health US, LLC | $136.08 | 2021-2023 | Aplenzin |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $120.86 | 2019-2024 | Adzenys Xr-Odt |
| Merck Sharp & Dohme LLC | $118.90 | 2020-2021 | |
| Adlon Therapeutics L.P. | $113.97 | 2020-2021 | |
| Indivior INC. | $57.29 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $55.28 | 2023-2024 | Quviviq |
| Supernus Pharmaceuticals, INC. | $53.61 | 2021-2024 | Qelbree, Qelbree |
| Corium, LLC | $49.30 | 2025 | Azstarys |
| Shire North American Group INC | $44.02 | 2019 | |
| Avanir Pharmaceuticals, INC. | $39.74 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $36.70 | 2025 | Cobenfy |
| Neuronetics, INC. | $29.35 | 2019-2020 | |
| Lilly USA, LLC | $22.82 | 2022 | |
| Noven Therapeutics, LLC | $21.61 | 2024 | Xelstrym, Secuado |
| Braeburn INC. | $20.12 | 2024 | Brixadi |
| Alfasigma USA, INC. | $14.85 | 2022 | |
| Tempus Ai, INC | $13.16 | 2024 | |
| Janssen Biotech, INC. | $10.18 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mariana Danet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.